Ashfield announces the launch of EmerGENE, a global end-to-end cell and gene therapy network approach which promises to support small and midsize biotechs with the commercialization of their discoveries.
The first of its kind in the industry, EmerGENE has been built by a multidisciplinary team that delivers expert-led guidance and services to biotechs throughout their entire clinical to commercial journey and beyond.
Combining experts from Ashfield Advisory, Ashfield Engage and Ashfield Health, EmerGENE aims to unlock the potential of cell and gene therapy helping drug developers to bring transformational treatments to patients. This includes select experts from Ashfield Advisory who will consult and support on the development of commercial and organizational approach for companies planning their cell and gene therapy product launch and market access strategies.
Colin Stanley, President at Ashfield Advisory, said: “We enjoy crafting actionable solutions molded to the needs of our customers and the nuances of bringing cell and gene therapy products to market and into the hands of patients presents unique challenges and ways of working. We’re lucky to have some very experienced people in this space working across Ashfield to deliver comprehensive solutions is exciting and relevant.”
“As the first network approach to provide a unique, end-to-end offering, EmerGENE will provide experience and perspectives that will benefit both new and existing customers and help them achieve commercial success for these innovative therapies.”
EmerGENE will provide guidance on all areas, including commercialization strategic support, early clinical development guidance, distribution and logistics, market access and patient and HCP engagement and support.
The experts at EmerGENE have supported five of the six current commercialized cell and gene therapy products on their journey to market.
Global EmerGENE lead, Ben Beckley said: “When it comes to cell and gene therapies, we know that every moment matters. In many cases, these therapies are a last chance for patients and their families so helping innovators get their discoveries to patients with as much ease as possible is truly vital work.
“EmerGENE’s perfectly tailored teams bring together entrepreneurial expertise and mentorship alongside logistical and practical capabilities in order to find the correct path – not just providing advice but executing solutions and ultimately realizing the awesome potential of cell and gene therapies for patients and their families.”
For more information, or to find out how EmerGENE can support your business, please visit: http://www.oneashfield.com
Read how we assessed the commercial opportunity for a new CAR-T therapy.
Read moreDisharee Nath, PhD, Associate Medical Director at Mind+Matter, attended the two-day Cell & Gene Therapy USA (Sep ’21) conference organized by Reuters.
Read more